Page 4 - Flipbook

Learning Objectives

At the end of this presentation, participants will be able to:

• Describe Canadian guidelines on the management of muscle-invasive bladder

cancer (MIBC) in order to maximize cure rates

• Identify patients with MIBC who are eligible for neoadjuvant and

adjuvant therapy using a multidisciplinary and patient-centered approach

• Assess the latest clinical trial data investigating immune checkpoint inhibitors

in the neoadjuvant and adjuvant settings in patients with MIBC